The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Nurix Therapeutics Inc (NASDAQ: NRIX) closed at $12.45 up 1.59% from its previous closing price of $12.26. In other words, the price has increased by $1.59 from its previous closing price. On the day, 1.5 million shares were traded. NRIX stock price reached its highest trading level at $13.03 during the session, while it also had its lowest trading level at $11.98.
Ratios:
For a deeper understanding of Nurix Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.35 and its Current Ratio is at 5.35. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Mizuho on October 21, 2025, initiated with a Outperform rating and assigned the stock a target price of $24.
On March 17, 2025, Leerink Partners started tracking the stock assigning a Market Perform rating and target price of $16.
On December 10, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $35.BTIG Research initiated its Buy rating on December 10, 2024, with a $35 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 03 ’25 when van Houte Hans sold 6,284 shares for $12.56 per share. The transaction valued at 78,931 led to the insider holds 37,592 shares of the business.
JOHANNES VAN HOUTE bought 6,284 shares of NRIX for $81,315 on Nov 03 ’25. On Oct 30 ’25, another insider, van Houte Hans, who serves as the Chief Financial Officer of the company, sold 3,130 shares for $12.80 each. As a result, the insider received 40,054 and left with 43,876 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NRIX now has a Market Capitalization of 1262553728 and an Enterprise Value of 585240192. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.09 while its Price-to-Book (P/B) ratio in mrq is 2.57. Its current Enterprise Value per Revenue stands at 6.993 whereas that against EBITDA is -2.256.
Stock Price History:
The Beta on a monthly basis for NRIX is 1.92, which has changed by -0.5499266 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, NRIX has reached a high of $29.56, while it has fallen to a 52-week low of $8.18. The 50-Day Moving Average of the stock is 25.77%, while the 200-Day Moving Average is calculated to be 4.40%.
Shares Statistics:
For the past three months, NRIX has traded an average of 1.23M shares per day and 2663260 over the past ten days. A total of 101.37M shares are outstanding, with a floating share count of 99.32M. Insiders hold about 2.02% of the company’s shares, while institutions hold 87.48% stake in the company. Shares short for NRIX as of 1760486400 were 13868490 with a Short Ratio of 11.23, compared to 1757894400 on 13045894. Therefore, it implies a Short% of Shares Outstanding of 13868490 and a Short% of Float of 21.17.
Earnings Estimates
Current recommendations for the stock of the company come from 15.0 analysts. The consensus estimate for the next quarter is -$0.86, with high estimates of -$0.66 and low estimates of -$1.05.
Analysts are recommending an EPS of between -$2.94 and -$3.39 for the fiscal current year, implying an average EPS of -$3.16. EPS for the following year is -$3.58, with 15.0 analysts recommending between -$2.13 and -$4.46.
Revenue Estimates
For the next quarter, 17 analysts are estimating revenue of $16.33M. There is a high estimate of $22.5M for the next quarter, whereas the lowest estimate is $13.8M.
A total of 17 analysts have provided revenue estimates for NRIX’s current fiscal year. The highest revenue estimate was $108.78M, while the lowest revenue estimate was $70.4M, resulting in an average revenue estimate of $85.04M. In the same quarter a year ago, actual revenue was $54.55M
